Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Episode 13 with Professor Alan Thompson on the International Progressive MS Alliance.
Keystone Symposium: Gut Microbiota Modulation of Host Physiology: The Search for Mechanism
American Academy of Neurology: Breakthroughs in Neurology
MS Research Roundup: An Introduction
Episode 12 with Professor Gavin Giovannoni on the potential for finding a cure for MS.
Pregnancy and multiple sclerosis.
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.
Biogen Idec to acquire Fumapharm AG; Consolidates ownership of oral compound BG-12 being studied for multiple sclerosis
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial
SJL mice exposed to cuprizone intoxication reveal strain and gender pattern differences in demyelination.
A New Colour Reaction on Copper and Certain Carbonyl Compounds
MS clinical trials: what can subgroup analyses teach us?
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.
Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model.
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.
Episode 18 with Dr. Samuel Ludwin on new approaches to remyelination therapies.
Masitinib mesylate application for conditional approval
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.

Pages